Sarah Leggett1, Antje van der Zee-Neuen1, Annelies Boonen1, Dorcas E Beaton1, Mihai Bojinca1, Ailsa Bosworth1, Sabrina Dadoun1, Bruno Fautrel1, Sofia Hagel1, Catherine Hofstetter1, Diane Lacaille1, Denise Linton1, Carina Mihai1, Ingemar F Petersson1, Pam Rogers1, Jamie C Sergeant1, Carlo Sciré1, Suzanne M M Verstappen1. 1. From the Arthritis Research UK Centre for Epidemiology, Manchester Academic Health Science Centre, University of Manchester, Manchester, UK; Department of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute, Maastricht University, The Netherlands; Mobility Program Clinical Research Unit, St. Michael's Hospital, Toronto, Ontario, Canada; Internal Medicine and Rheumatology Clinic, Dr. Ion Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; National Rheumatoid Arthritis Society, Maidenhead, UK; Department of Rheumatology, Université Pierre et Marie Curie, Paris, France; Department of Clinical Sciences Lund, Section of Rheumatology, Lund University and Skane University Hospital, Lund, Sweden; Canadian Arthritis Patient Alliance, Toronto, Ontario, Canada; Arthritis Research Centre of Canada, Division of Rheumatology, University of British Columbia, Vancouver, BC, Canada; Orthopaedics, Clinical Sciences Lund, Lund University, Lund, Sweden; NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK; Epidemiology Unit, Italian Society for Rheumatology, Milan, Italy; and the Arthritis Research UK/MRC Centre for Musculoskeletal Health and Research, University of Southampton, Southampton, UK.S. Leggett, MSc, Arthritis Research UK Centre for Epidemiology; A. van der Zee-Neuen, PhD, Department of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; A. Boonen, MD, PhD, Professor of Rheumatology, Department of Rheumatology, Maastricht University Medical Centre, and Caphri Research Institute; D.E. Beaton, PhD, Mobility Program Clinical Research Unit, St. Michael's Hospital; M. Bojinca, MD, PhD, Internal Medicine and Rheumatology Clinic, Dr. Ion Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy; A. Bosworth, Patient Partner, National Rheumatoid A
Abstract
OBJECTIVE: Several global measures to assess at-work productivity loss or presenteeism in patients with rheumatic diseases have been proposed, but the comparative validity is hampered by the lack of data on test-retest reliability and comparative concurrent and construct validity. Our objective was to test-retest 5 global measures of presenteeism and to compare the association between these scales and health-related well-being. METHODS: Sixty-five participants with inflammatory arthritis or osteoarthritis in paid employment were recruited from 7 countries (UK, Canada, Netherlands, France, Sweden, Romania, and Italy). At baseline and 2 weeks later, 5 global measures of presenteeism were evaluated: the Work Productivity Scale-Rheumatoid Arthritis (WPS-RA), Work Productivity and Activity Impairment Questionnaire (WPAI), Work Ability Index (WAI), Quality and Quantity questionnaire (QQ), and the WHO Health and Performance Questionnaire (HPQ). Agreement between the 2 timepoints was assessed using single-measure intraclass correlations (ICC) and correlated between each other and with visual analog scale general well-being scores at followup by Spearman correlation. RESULTS: ICC between measures ranged from fair (HPQ 0.59) to excellent (WPS-RA 0.78). Spearman correlations between measures were moderate (Qquality vs WAI, r = 0.51) to strong (WPS-RA vs WPAI, r = 0.88). Correlations between measures and general well-being were low to moderate, ranging from -0.44 ≤ r ≤ 0.66. CONCLUSION: Test-retest results of 4 out of 5 global measures were good, and the correlations between these were moderate. The latter probably reflect differences in the concepts, recall periods, and references used in the measures, which implies that some measures are probably not interchangeable.
OBJECTIVE: Several global measures to assess at-work productivity loss or presenteeism in patients with rheumatic diseases have been proposed, but the comparative validity is hampered by the lack of data on test-retest reliability and comparative concurrent and construct validity. Our objective was to test-retest 5 global measures of presenteeism and to compare the association between these scales and health-related well-being. METHODS: Sixty-five participants with inflammatory arthritis or osteoarthritis in paid employment were recruited from 7 countries (UK, Canada, Netherlands, France, Sweden, Romania, and Italy). At baseline and 2 weeks later, 5 global measures of presenteeism were evaluated: the Work Productivity Scale-Rheumatoid Arthritis (WPS-RA), Work Productivity and Activity Impairment Questionnaire (WPAI), Work Ability Index (WAI), Quality and Quantity questionnaire (QQ), and the WHO Health and Performance Questionnaire (HPQ). Agreement between the 2 timepoints was assessed using single-measure intraclass correlations (ICC) and correlated between each other and with visual analog scale general well-being scores at followup by Spearman correlation. RESULTS: ICC between measures ranged from fair (HPQ 0.59) to excellent (WPS-RA 0.78). Spearman correlations between measures were moderate (Qquality vs WAI, r = 0.51) to strong (WPS-RA vs WPAI, r = 0.88). Correlations between measures and general well-being were low to moderate, ranging from -0.44 ≤ r ≤ 0.66. CONCLUSION: Test-retest results of 4 out of 5 global measures were good, and the correlations between these were moderate. The latter probably reflect differences in the concepts, recall periods, and references used in the measures, which implies that some measures are probably not interchangeable.
Authors: L M Fatti; B Cangiano; G Vitale; L Persani; G Mantovani; E Sala; M Arosio; P Maffei; F Dassie; M Mormando; A Giampietro; L Tanda; E R Masiello; E Nazzari; D Ferone; S Corbetta; E Passeri; F Guaraldi; S Grottoli; S Cannavò; M L T Torre; D Soranna; A Zambon; F Cavagnini; M Scacchi Journal: Pituitary Date: 2019-10 Impact factor: 4.107
Authors: Timo T Beemster; Judith M van Velzen; Coen A M van Bennekom; Michiel F Reneman; Monique H W Frings-Dresen Journal: J Occup Rehabil Date: 2019-03
Authors: James M Gwinnutt; Sarah Leggett; Mark Lunt; Anne Barton; Kimme L Hyrich; Karen Walker-Bone; Suzanne M M Verstappen Journal: Rheumatology (Oxford) Date: 2020-10-01 Impact factor: 7.580